You are here:

MS in the media - 17 February 2017

Published on

11 - 17 February 2017

These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.

Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.

To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts

Disease modifying drugs and clinically isolated syndrome

A study found that people who took Rebif (interferon beta 1a) following a first episode of neurological symptoms (CIS) were less likely to have converted to a definite diagnosis of MS after five years.

Source: MSIF

MS Trust link: Clinically isolated syndrome (CIS)

Fampridine response changes over time

A study found that the improved walking speed and stamina seen in a clinical trial of fampridine (Fampyra/Ampyra) were maintained over a further year.  A third of people who had initially been poor responders to the drug did better in the longer-term

Source: MedPage Today

MS Trust link: Fampridine

Disability assistance at airports lacking

A woman with MS is included in a BBC Wales investigation into Omniserv, the company providing assistance at airports for people with a disability. The report found poor lifting practices and people being left for long periods with no help

Source: BBC

MS Trust link: Travelling and holidays

Disease modifying drugs compared

An international study compared Lemtrada (alemtuzumab) with Tysabri (natalizumab), Gilenya (fingolimod) and Rebif. The relapse rate on Lemtrada was lower than that for Gilenya and Rebif, though similar to that for Tysabri. The risk of disability accumulation was similar across all four drugs. The chance for periods of improvement in disability was higher with Tysabri, with the other three drugs roughly the same

Source: MedWire News

MS Trust link: MS Decisions - a guide to the disease modifying drugs for relapsing MS

Print this page